Article Text

PDF
Research paper
Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation
  1. Bianca Weinstock-Guttman1,2,
  2. Jesper Hagemeier3,
  3. Katelyn S Kavak1,
  4. Vasu Saini1,
  5. Kara Patrick1,
  6. Deepa P Ramasamy3,
  7. Muhammad Nadeem1,
  8. Ellen Carl3,
  9. David Hojnacki1,
  10. Robert Zivadinov2,3,4
  1. 1Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo, Buffalo, New York, USA
  2. 2Department of Neurology, State University of New York at Buffalo, Buffalo, New York, USA
  3. 3Department of Neurology, Buffalo Neuroimaging Analysis Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA
  4. 4MR Imaging Clinical Translational Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA
  1. Correspondence to Dr Bianca Weinstock-Guttman, Jacobs MS Center for Treatment and Research, 100 High Street, Buffalo, NY 14203, USA; bw8{at}buffalo.edu

Abstract

Objectives To compare two modes of natalizumab cessation interventions: immediate versus tapered down, as measured by serial MRI and the occurrence of relapses during a 12-month period.

Background Weighing progressive multifocal encephalopathy risk associated with ≥24 months of natalizumab therapy against the benefits of disease control, we initiated a natalizumab discontinuation study.

Methods A phase IV, 12-month, single-blinded randomised (MRI) study. Fifty relapsing patients with multiple sclerosis (MS) who had been on natalizumab therapy ≥24 months and were contemplating natalizumab discontinuation were enrolled. Participants were randomised to either the immediate discontinuation group (IDG) or the tapered group (TG). IDG discontinued natalizumab at once and initiated another disease modifying therapy (DMT) following the last natalizumab infusion, while the TG received two more natalizumab infusions, at 6 and 8 weeks (14 weeks from study entry) before initiating another DMT. Standardised MRI was performed at baseline, 6 and 12 months from the last natalizumab infusion.

Results A higher rate of relapses in the IDG (n=28) compared to the TG (n=8) over 12 months from the last infusion (p=0.007) was observed, most relapses occurred within 3 months of discontinuation (20 vs 7 relapses, p=0.012). The IDG showed a higher number of new T2 lesions within 6–12 months of discontinuation (p=0.025), a higher mean absolute T2-LV change from 0 to 12 months (1.1 vs 0.1 mL, p=0.024) and a higher number of new T1-hypointense lesions over 0–12 months (p=0.005) as well as from baseline to 6 months (p=0.026) compared to the TG.

Conclusions Natalizumab discontinuation therapy was associated with development of new disease activity. Our tapered protocol showed benefits, as patients in the TG experienced less relapses and lower accumulation of MRI lesions compared to those in the IDG.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.